Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. Carmona-Rocha E, Sullivan I, Yelamos O. Melanoma Res 2023;33:553-555.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Carmona-Rocha E, Sullivan I, Yelamos O. Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. Melanoma Res 2023;33:553-555.
PMID: 37890183